Welcome to our dedicated page for Syros Pharmaceut news (Ticker: SYRS), a resource for investors and traders seeking the latest updates and insights on Syros Pharmaceut stock.
Syros Pharmaceuticals (SYRS) is a leader in gene regulation research, developing novel therapies for oncology and hematologic malignancies through its integrated platform of assay technologies and bioinformatics. This page provides centralized access to all official company announcements, press releases, and third-party analyses related to SYRS's scientific advancements and corporate developments.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes updates on SYRS's drug discovery pipeline, financial results, and peer-reviewed research collaborations – all organized for efficient tracking of the company's progress in transforming gene control insights into therapeutic solutions.
Key content categories include clinical trial announcements, FDA regulatory updates, partnership disclosures with academic institutions, quarterly earnings reports, and scientific conference presentations. Each entry is verified for accuracy and relevance to SYRS's core mission of advancing precision medicine through gene regulatory circuit mapping.
Bookmark this page for streamlined monitoring of SYRS's developments in hematologic and oncology research. Check back regularly for authoritative updates on how Syros Pharmaceuticals continues to pioneer new approaches in targeted drug discovery.
Syros Pharmaceuticals (SYRS) announced promising preclinical results for its CDK12 inhibitor program, showcasing strong anti-tumor activity in breast, lung, and ovarian cancer models. The data, presented at the AACR Annual Meeting 2022, indicate that the CDK12 inhibitors have low nanomolar potency and selectivity against other CDKs. The inhibitors demonstrated significant tumor regression in animal models and synergy with DNA damaging agents. Syros plans to nominate a development candidate in the second half of 2022, targeting patients resistant to current therapies.
Syros Pharmaceuticals (NASDAQ: SYRS) announced the grant of restricted stock unit (RSU) awards totaling 89,400 shares to three new employees as inducements for employment, in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs vest over four years, with one-quarter of the shares vesting on each anniversary of the grant date, contingent on continued service. This strategic move aims to attract talent as the company advances its clinical-stage pipeline targeting gene expression control in various cancers.
Syros Pharmaceuticals (SYRS) reported Q4 and full-year 2021 financial results, highlighting a net loss of $23.8 million for Q4 and $86.6 million for the year. Total revenues were $7.8 million in Q4 and $23.5 million for 2021, up from $5.7 million and $15.1 million respectively in 2020. Key upcoming milestones include reporting pharmacokinetic and safety data for SY-2101 and clinical activity from SY-5609 in pancreatic cancer in mid-2022. Syros maintains $143.4 million in cash, expected to cover operations into Q1 2023.
Syros Pharmaceuticals (NASDAQ:SYRS) is set to host a live conference call and webcast on March 15, 2022, at 8:30 a.m. ET, to discuss its fourth quarter and full year 2021 financial results. The call can be accessed via phone at (866) 595-4538 for domestic calls and (636) 812-6496 internationally, using conference ID 9682507. Syros is advancing a clinical-stage pipeline with key products like tamibarotene and SY-2101 targeting myeloid malignancies and acute promyelocytic leukemia, respectively. A webcast will be available for 30 days post-event on Syros’ website.
Syros Pharmaceuticals (NASDAQ:SYRS) announced the presentation of new preclinical data on its CDK12 inhibitor program at the AACR Annual Meeting 2022, scheduled from April 8-13 in New Orleans, Louisiana. The e-poster will reveal that the selective CDK12 inhibitor exhibits strong anti-tumor activity both in vitro and in vivo across various cancer models and shows improved effects when combined with DNA-damaging agents. Syros aims to nominate a development candidate from this program in the latter half of 2022.
Syros Pharmaceuticals (NASDAQ:SYRS) announced that CEO Nancy Simonian will participate in two virtual investor conferences in March. She will present at the Cowen 42nd Annual Healthcare Conference on March 7 at 12:50 p.m. ET and at the Oppenheimer 32nd Annual Healthcare Conference on March 16 at 3:20 p.m. ET. Management will also hold one-on-one meetings. Archived recordings will be available on Syros' website.
Syros focuses on developing gene expression medicines with a diverse clinical pipeline, including treatments for myelodysplastic syndrome, acute myeloid leukemia, and solid tumors.
Syros Pharmaceuticals (NASDAQ:SYRS) has announced that the U.S. FDA granted orphan drug designation to tamibarotene for treating myelodysplastic syndrome (MDS). Tamibarotene, a selective retinoic acid receptor alpha agonist, is being evaluated in the SELECT-MDS-1 Phase 3 trial alongside azacitidine for RARA-positive HR-MDS patients. The drug's designation may offer benefits including market exclusivity and tax credits. Data from the trial is expected in late 2023 or early 2024, with potential new drug application filing anticipated in 2024.
Syros Pharmaceuticals (NASDAQ: SYRS) has announced significant advancements in its clinical programs. The company initiated an expansion cohort for SY-5609 combined with chemotherapy for pancreatic cancer patients, with results expected in late 2022. Additionally, a Phase 1 trial for SY-5609 in hematologic malignancies is set to begin in the second half of 2022, alongside the nomination of a new development candidate from the CDK12 program. Syros remains optimistic about three key clinical data readouts in 2022 and is in a strong financial position to support operations into 2023.
Syros Pharmaceuticals (NASDAQ:SYRS) announced that CEO Nancy Simonian will participate in fireside chats at two virtual investor conferences. The Piper Sandler 33rd Annual Healthcare Conference will take place on November 23, 2021, with a pre-recorded chat available on-demand at 10:00 a.m. ET. The JMP Securities Hematology and Oncology Summit is scheduled for December 6, 2021, at 10:40 a.m. ET. Webcasts and archived recordings can be accessed on Syros' website. The company is focused on developing gene expression medicines and has a robust clinical pipeline.
Syros Pharmaceuticals (NASDAQ:SYRS) announced significant progress in its clinical trials, including the dosing of the first patient in the SELECT-AML-1 Phase 2 trial of tamibarotene and the dose confirmation study of SY-2101 in acute promyelocytic leukemia (APL). Financial results for Q3 2021 revealed revenues of $5.7 million, up from $3.8 million in Q3 2020, though the company reported a net loss of $26 million. Notably, SY-5609 showed clinical activity in difficult-to-treat tumors during a recent Phase 1 trial. The company expects existing funds to sustain operations into 2023.